This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 16 of 34 for:    ponatinib

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. (LAL1811)

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by Gruppo Italiano Malattie EMatologiche dell'Adulto
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto Identifier:
First received: July 12, 2012
Last updated: September 14, 2016
Last verified: September 2016
Drug resistance resulting from emergence of Imatinib-resistant BCR-ABL clones is a significant problem in Ph positive ALL patients because after a very good initial response to one TKI inhibitor, many patients relapse within one year, relapse being almost always associated with a BCR-ABL kinase domain point mutation. The patients who relapse after treatment with one TKI can be rescued to remission with another TKI, but the second remission is usually shorter than the previous one. A more potent TKI inhibitor, and pan-active not only on all the BCR-ABL variants (including the second generation TKI resistant T315I mutant), but also on others molecular targets can do better. In this context, Ponatinib is a novel synthetic orally active tyrosine kinase inhibitor (TKI), specifically developed to inhibit BCR-ABL, the fusion protein that is the product of the Philadelphia chromosome (Ph) in chronic myeloid leukemia (CML) and in a subset of acute lymphoblastic leukemia (Ph+ ALL). It potently inhibits the BCR-ABL protein as well as mutated forms of the protein that arise in patients resistant to prior therapies with TKIs. Ponatinib has been demonstrated to inhibit all the mutations that have been detected so far, in vitro and in vivo and to uniformly suppress the emerge of single-mutant clones in a mutagenesis assay. In the Phase II study, 41% of Philadelphia chromosome positive acute lymphoblastic leukemia patients treated with Ponatinib achieved major hematologic response, 47% had a major cytogenetic response, 38% obtained a complete cytogenetic response, showing that Ponatinib provides significant benefit despite previous intolerance or refractoriness to other TKIs. The Phase I trial showed that patients with a more recent diagnosis had increased rates of major molecular response: 79% for 14 patients with 0 to 5 years since diagnosis vs. 29% for 14 patients with more than 5 to 9 years since diagnosis (P=0.02) and 27% for 15 patients with more than 9 to 24 years since diagnosis (P=0.009). These characteristics support the hypothesis for a role of Ponatinib not only in patients resistant to prior TKI therapy but also in untreated ALL Ph+ patients, in order to prevent the emergence of resistant caused by the selection of mutated Ph+ clones and in order to avoid rapid progression of the disease.

Condition Intervention Phase
Philadelphia Positive BCR-ABL Positive Acute Lymphoblastic Leukemia Drug: Ponatinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.

Resource links provided by NLM:

Further study details as provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:

Primary Outcome Measures:
  • Proportion of patients who are in Complete Hematological Response (CHR). [ Time Frame: At 6 months from study entry. ]
    The primary endpoint is the proportion of patients who are in CHR at 6 months, calculated on the total number of patients who have been enroled and have received at least one dose of the first drug (prednisone).

Secondary Outcome Measures:
  • The rate of Complete Hematological Response (CHR). [ Time Frame: At 6, 12, 24, 36 and 48 weeks from study entry. ]

    CHR requires that all of the following are present:

    • Bone marrow with less than 5% blast cells
    • Peripheral blood differential without blasts
    • PMN ≥ 1.5 x 109/L
    • PLT ≥ 100 x 109/L
    • No evidence of extramedullary involvement from leukemia

  • The rate of complete Cytogenetic Response (CgR). [ Time Frame: At 6, 12, 24, 36 and 48 weeks from study entry. ]

    CgR is defined based on the percentage of Ph pos metaphases, as evaluated by chromosome banding analysis (CBA) of at least 20 marrow cell metaphases:

    1. Complete (CCgR) if Ph pos 0
    2. Partial (PCgR) if Ph pos 1-34%
    3. Minor (mCgR) if Ph pos 35-65%
    4. Minimal or none (min/none CgR) if Ph pos > 65% If only interphase FISH data are available, the response can be defined only as non-complete or complete - to be complete by FISH, it is required that less than 1% of nuclei (minimum number 200) have a positive signal.

  • Duration of Complete Cytogenetic Response (CCgR). [ Time Frame: After four years from study entry. ]
    Duration of CCgR is measured by the date of the achievement of CCgR to the date of CCgR loss.

  • The rate of Complete Molecular Response (CMoIR). [ Time Frame: At 12, 24, 36 and 48 weeks from study entry. ]

    Molecular response is classified as:

    • Complete if by RT-Q-PCR the BCR-ABL: ABL ratio is below 0.01, with a sensitivity of at least 30,000 molecules of ABL.

  • The rate of major molecular response. [ Time Frame: At 12, 24, 36 and 48 weeks from study entry. ]

    Molecular response (MR) is classified as:

    • Major (MMolR) if by RT-Q-PCR the BCR-ABL: ABL ratio is lower than 0.10, with a sensitivity of at least 30,000 molecules of ABL.

  • Duration of Complete molecular response (CMR). [ Time Frame: After four years from study entry. ]
    Duration of CMR is measured by the date of the achievement of CMR to the date of CMR loss.

  • Type and number of BCR-ABL kinase domain mutations. [ Time Frame: At the end of the study. At four years after enrollment of first patient. ]
  • Percentage of relationships between the response and the biomarkers. [ Time Frame: At six months from study entry. ]
  • Event Free Survival. [ Time Frame: After four years from study entry. ]
    Events are induction failure, relapse and death whichever comes first.

  • Overall survival [ Time Frame: At the end of study. After four years from enrolment. ]
    Overall survival is measured in all patients from the data of enrolment to the date of death, by any causes.

  • Failure Free Survival [ Time Frame: After four years from study entry. ]
  • Rate of Rate of side effects, adverse events and serious adverse events. [ Time Frame: After four years from study entry. ]

Estimated Enrollment: 44
Study Start Date: October 2014
Estimated Study Completion Date: November 2019
Estimated Primary Completion Date: November 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ponatinib Drug: Ponatinib


Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion.

Detailed Description:

This is a multi-center, phase 2, single arm unblinded trial of oral Ponatinib in patients with Ph+ Acute Lymphoblastic Leukemia. Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event.

Each patient should be treated for a minimum of 6 weeks. Then a patient can be discontinued in the following situation:

  • at the end of first course (6 weeks), in case of lack of CHR;
  • at the end of third course (18 weeks), in case of lack of CCgR;
  • any time in case of loss of CHR or CCgR.

If they remain on therapy after 48 weeks, they will be able to continue treatment during the extension phase of the study, if it is of interest of the patient, or they will be allowed to receive any treatment that is in their interest. For all the patients remaining on trial, response, outcome and toxicity will be followed for the subsequent 24 months.The 6-weeks periodicity must be rigidly respected, irrespective of the temporary discontinuation of study drug (eg, if a patient will take Ponatinib only for 4 weeks and will remain off-treatment for the subsequent two weeks because of AE, when the 7th week begins this patient will restart Ponatinib as a second course, as per protocol). Prednisone (P) will be administered to all patients for 7-14 days, before Ponatinib, so as to make it possible to wait for the results of cytogenetic and molecular tests, and to evaluate the response to P alone, hence for another 21 days. Intrathecal therapy (IT) with MTX/AraC/DEX is mandatory, every 28 days, in patients without clinical-cytologic evidence of meningeal involvement. In patients with CNS disease, IT is performed twice weekly until a complete clearance of cerebrospinal fluid blast cells is achieved, hence once weekly for 4 weeks, hence once monthly.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. To be classified as having Ph+ ALL, patients must have >20% blasts in bone marrow at the time of diagnosis and no prior history of CML.
  2. Patients with previously untreated Ph+ and/or BCR/ABL + ALL:

    • age ≥ 60 years old or
    • age ≥ 18 years old, but unfit for program of intensive therapy and allogeneic SCT
  3. Adequate hepatic function as defined by the following criteria:

    • total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome
    • alanine aminotransferase (ALT) ≤2.5 × ULN
    • aspartate aminotransferase (AST) ≤2.5 × ULN.
  4. Adequate pancreatic function as defined by the following criterion:

    - serum lipase and amylase ≤1.5 × ULN.

  5. For females of childbearing potential, a negative pregnancy test must be documented prior to randomization.
  6. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment.
  7. Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

  1. WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).
  2. Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubin ≥ 1.5 x ULN.
  3. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis.
  4. History of alcohol abuse.
  5. Ongoing or active infections.
  6. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL).
  7. Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

    • any history of myocardial infarction, stroke, or revascularization
    • unstable angina or transient ischemic attack within 6 months prior to enrollment
    • congestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards within 6 months prior to enrollment
    • history of clinically significant (as determined by the treating physician) atrial arrhythmia
    • any history of ventricular arrhythmia
    • any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism .
  8. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
  9. Taking medications that are known to be associated with Torsades de Pointes.
  10. Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib.
  11. Creatinine level > 2.5mg/dl or Glomerular Filtration Rate (GFR) < 20 ml/min or proteinuria > 3.5 g/day.
  12. Impairment of gastrointestinal (GI) function, or a GI disease that may significantly alter the absorption of study drugs (e.g. rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption, severe malabsorption syndrome, or extended small bowel resection).
  13. Patients who are currently receiving treatment with any of the medications listed in Appendix E if the medications cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix E have the potential to prolong QT.
  14. Patients who have received any investigational drug ≤ 4 weeks.
  15. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  16. Patients who are pregnant or breast feeding and adults of reproductive potential not employing an effective method of birth control (women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of Ponatinib). Post menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 4 months following discontinuation of study drugs.
  17. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.
  18. Patients unwilling or unable to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01641107

Contact: Paola Fazi, Dr.
Contact: Enrico Crea

S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo Recruiting
Alessandria, Italy
Contact: Lorella Depaoli         
Principal Investigator: Lorella Depaoli         
Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI Recruiting
Ancona, Italy
Contact: Massimo Offidani         
Principal Investigator: Massimo Offidani         
Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni" Recruiting
Ascoli, Italy
Contact: Piero Galieni         
Principal Investigator: Piero Galieni         
Sub-Investigator: Catia Bigazzi         
Az.Ospedaliera S.G.Moscati Recruiting
Avellino, Italy
Contact: Nicola Cantore         
Principal Investigator: Nicola Cantore         
Sub-Investigator: Lidia Santoro         
Azienda Ospedaliera - Papa Giovanni XXIII Recruiting
Bergamo, Italy
Contact: Alessandro Rambaldi         
Principal Investigator: Alessandro Rambaldi         
Sub-Investigator: Tamara Intermesoli         
Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi Recruiting
Bologna, Italy
Contact: Giovanni Martinelli         
Principal Investigator: Giovanni Martinelli         
ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO Recruiting
Cagliari, Italy
Contact: Emanuele Angelucci, Pr.         
Principal Investigator: Emanuele Angelucci, Pr.         
Sub-Investigator: Claudio Romani, Dr.         
Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto" Recruiting
Catania, Italy
Contact: Francesco Di Raimondo, Pr.         
Principal Investigator: Francesco Di Raimondo, Pr.         
Sub-Investigator: Maria Rita, Dr.         
Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi Recruiting
Ferrara, Italy
Contact: Antonio Cuneo         
Principal Investigator: Antonio Cuneo         
Sub-Investigator: Gian Matteo Rigolin         
Policlinico di Careggi Recruiting
Firenze, Italy
Contact: Alberto Bosi, Pr.         
Principal Investigator: Alberto Bosi, Pr.         
Sub-Investigator: Antonella Gozzini, Dr.         
Divisione Ematologia 1 - Azienda Ospedaliera Universitaria "San Martino" Recruiting
Genova, Italy
Contact: Angelo Michele Carella, Pr.         
Principal Investigator: Angelo Michele Carella, Pr.         
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE Recruiting
Lecce, Italy
Contact: Nicola Di Renzo         
Principal Investigator: Nicola Di Renzo         
Sub-Investigator: Michelina Dargenio         
Unità Operativa Complessa - Medicina Generale - Sezione di Ematologia - Ospedale Versilia USL 12 Toscana Recruiting
Lido di Camaiore, Italy
Contact: Federico Simonetti         
Principal Investigator: Federico Simonetti         
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST Recruiting
Meldola, Italy
Contact: Maria Benedetta Giannini         
Principal Investigator: Maria Benedetta Giannini         
U.O. di Ematologia- Ospedale dell'Angelo - Mestre Recruiting
Mestre, Italy
Contact: Renato Bassan         
Principal Investigator: Renato Bassan         
Ospedale Niguarda " Ca Granda" Recruiting
Milano, Italy
Contact: Alessandra Tedeschi         
Principal Investigator: Alessandra Tedeschi         
Sub-Investigator: Elisa Roncoroni         
UO Ematologia - AOU Policlinico di Modena Recruiting
Modena, Italy
Contact: Mario Luppi         
Principal Investigator: Mario Luppi         
Sub-Investigator: Monica Morselli         
S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro Recruiting
Novara, Italy
Contact: Gianluca Gaidano         
Principal Investigator: Gianluca Gaidano         
Sub-Investigator: Monia Lunghi         
Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 Recruiting
Orbassano, Italy
Contact: Giovanna Rege         
Principal Investigator: Giovanna Rege         
Università degli Studi di Padova - Ematologia ed Immunologia Clinica Recruiting
Padova, Italy
Contact: Pietro Semenzato         
Principal Investigator: Pietro Semenzato         
Ospedali Riuniti "Villa Sofia-Cervello" Recruiting
Palermo, Italy
Contact: Francesco Fabbiano, Pr.         
Principal Investigator: Francesco Fabbiano, Pr.         
Sub-Investigator: Rosaria Felice, Dr.         
S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo Recruiting
Pavia, Italy
Contact: Carlo Castagnola, Pr.         
Principal Investigator: Carlo Castagnola, Dr.         
Sub-Investigator: Marianna Rossi, Dr.         
Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia Recruiting
Perugia, Italy
Contact: Brunangelo Falini         
Principal Investigator: Brunangelo Falini         
Sub-Investigator: Maria Paola Martelli         
Div. di Ematologia di Muraglia - CTMO Ospedale San Salvator Recruiting
Pesaro, Italy
Contact: Giuseppe Visani         
Principal Investigator: Giuseppe Visani         
Sub-Investigator: Alessandro Isidori         
U.O. Ematologia Clinica - Azienda USL di Pescara Recruiting
Pescara, Italy
Contact: Giuseppe Fioritoni         
Principal Investigator: Giuseppe Fioritoni         
Sub-Investigator: Anna Recchia         
Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza Recruiting
Piacenza, Italy
Contact: Daniele Vallisa, Pr.         
Principal Investigator: Daniele Vallisa, Pr.         
Sub-Investigator: Elena Trabacchi, Dr.         
Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia Recruiting
Pisa, Italy
Contact: Mario Petrini         
Principal Investigator: Mario Petrini         
Dipartimento Oncologico - Ospedale S.Maria delle Croci Recruiting
Ravenna, Italy
Contact: Alfonso Zaccaria, Pr.         
Principal Investigator: Alfonso Zaccaria, Pr.         
Sub-Investigator: Eliana Zuffa, Dr.         
Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli" Recruiting
Reggio Calabria, Italy
Contact: Francesca Ronco         
Principal Investigator: Francesca Ronco         
Ospedale "Infermi" Recruiting
Rimini, Italy
Contact: Patrizia Tosi         
Principal Investigator: Patrizia Tosi         
Sub-Investigator: Anna Maria Mianulli         
Complesso Ospedaliero S. Giovanni Addolorata Recruiting
Roma, Italy
Contact: Anna Chierichini         
Principal Investigator: Anna Chierichini         
Sub-Investigator: Elia Bongarzoni         
S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena Recruiting
Roma, Italy
Contact: Antonio Spadea         
Principal Investigator: Antonio Spadea         
Sub-Investigator: Atelda Romano         
U.O.C. Ematologia - Ospedale S.Eugenio Recruiting
Roma, Italy
Contact: Paolo De Fabrittiis         
Principal Investigator: Paolo De Fabrittiis         
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia Recruiting
Roma, Italy
Contact: Roberto Foà         
Principal Investigator: Roberto Foà         
Università degli Studi - Policlinico di Tor Vergata Recruiting
Roma, Italy
Contact: Sergio Amadori, Pr.         
Principal Investigator: Sergio Amadori, Pr.         
Sub-Investigator: Adriano Venditti, Pr.         
UOC di Ematologia e Trapianti di Cellule Staminali Emopoietiche - AOU San Giovanni di Dio e Ruggi D'Aragona Recruiting
Salerno, Italy
Contact: Carmine Selleri         
Principal Investigator: Carmine Selleri         
Sub-Investigator: Bianca Serio         
U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte" Recruiting
Siena, Italy
Contact: Monica Bocchia         
Principal Investigator: Monica Bocchia         
Sub-Investigator: Marzia Defina         
Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista Recruiting
Torino, Italy
Contact: Stefano D'ardia         
Principal Investigator: Stefano D'ardia         
Azienda U.L.S.S.9 - U.O. di Ematologia Recruiting
Treviso, Italy
Contact: Filippo Gherlinzoni         
Principal Investigator: Filippo Gherlinzoni         
Sub-Investigator: Federico Mosna         
Clinica Ematologica - Policlinico Universitario Recruiting
Udine, Italy
Contact: Anna Candoni, Dr.         
Principal Investigator: Anna Candoni, Dr.         
Sub-Investigator: Erica Simeone, Dr.         
Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi Recruiting
Verona, Italy
Contact: Giovanni Pizzolo, Pr.         
Principal Investigator: Giovanni Pizzolo, Pr.         
Sub-Investigator: Massimiliano Bonifacio, Dr.         
ULSS N.6 Osp. S. Bortolo Recruiting
Vicenza, Italy
Contact: Eros Di Bona         
Principal Investigator: Eros Di Bona         
Sponsors and Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
Principal Investigator: Michele Baccarani, Pr. Dpt of Hematology and Oncology "Seràgnoli", "Sant'Orsola-Malpighi" University Hospital of Bologna
  More Information

Additional Information:
Responsible Party: Gruppo Italiano Malattie EMatologiche dell'Adulto Identifier: NCT01641107     History of Changes
Other Study ID Numbers: LAL1811
2012-002761-35 ( EudraCT Number )
Study First Received: July 12, 2012
Last Updated: September 14, 2016

Keywords provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:
stem cell transplantation

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 16, 2017